EMD 57445: A Selective Sigma Receptor Ligand with the Profile of an Atypical Neuroleptic

This publication has 33 references indexed in Scilit:

• P-4-14 Pharmacology of the potential antipsychotic EMD 57445 in animals and humans
  European Neuropsychopharmacology, 1995
• DTG-induced circling behaviour in rats may involve the interaction between σ sites and nigro-striatal dopaminergic pathways
  Neuropharmacology, 1995
• Effects of typical and atypical neuroleptics on Fos protein expression in the rat forebrain
  Neuroscience Letters, 1994
• Mechanisms of action of atypical antipsychotic drugs: Implications for novel therapeutic strategies for schizophrenia
  Schizophrenia Research, 1991
• Inactivation of dopamine D-1 or D-2 receptors differentially inhibits stereotypies induced by dopamine agonists in rats
  European Journal of Pharmacology, 1988
• Activation of the A10 mesolimbic system by the σ-receptor agonist (+)SKF 10,047 can be blocked by rimcazole, a novel putative antipsychotic
  European Journal of Pharmacology, 1988
• Dopamine neurochemical profile of atypical antipsychotics resembles that of D-1 antagonists
  Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1988
• Mesolimbic and mesocortical dopamine activation induced by phencyclidine: contrasting pattern to striatal response
  European Journal of Pharmacology, 1987
• Evidence that the potential antipsychotic agent rimcazole (BW 234U) is a specific, competitive antagonist of sigma sites in brain
  Life Sciences, 1986
• BW234U,(cis-9-[3–(3,5-dimethyl-1-piperazinyl)propyl]carbazole dihydrochloride): a novel antipsychotic agent
  Journal of Pharmacy and Pharmacology, 1982